Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,036,301
  • Shares Outstanding, K 622,403
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,400 K
  • 60-Month Beta -0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CYDY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +20.00%
on 07/16/21
1.9500 -16.92%
on 07/21/21
-0.1200 (-6.90%)
since 06/25/21
3-Month
1.3500 +20.00%
on 07/16/21
3.2000 -49.38%
on 05/03/21
-1.5500 (-48.90%)
since 04/26/21
52-Week
1.3500 +20.00%
on 07/16/21
7.4000 -78.11%
on 02/02/21
-3.7800 (-70.00%)
since 07/24/20

Most Recent Stories

More News
CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY : 1.6200 (-2.70%)
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today...

CYDY : 1.6200 (-2.70%)
CytoDyn's Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks

CYDY : 1.6200 (-2.70%)
Proactive news headlines including Else Nutrition, Vanstar Mining, Mawson Gold, Psyched Wellness and CytoDyn

Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

CYDY : 1.6200 (-2.70%)
CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY : 1.6200 (-2.70%)
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV

Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications

CYDY : 1.6200 (-2.70%)
Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction

--Sends Letter to Stockholders Urging Support of Nominees With Deeply Relevant Experience and Critical Independent Perspectives

CYDY : 1.6200 (-2.70%)
Lawsuit for Investors in CytoDyn Inc. (OTCQB:CYDY) shares announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / June 22, 2021 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in CytoDyn Inc. shares.

CYDY : 1.6200 (-2.70%)
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY : 1.6200 (-2.70%)
CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY : 1.6200 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1.8567
2nd Resistance Point 1.7733
1st Resistance Point 1.6967
Last Price 1.6200
1st Support Level 1.5367
2nd Support Level 1.4533
3rd Support Level 1.3767

See More

52-Week High 7.4000
Fibonacci 61.8% 5.0889
Fibonacci 50% 4.3750
Fibonacci 38.2% 3.6611
Last Price 1.6200
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar